discuss with doctor if severe Week 1316: Maintenance Dose (9mg or continuing to 12mg) For 9mg group (maintenance): Side effects stabilize Nausea decreases (2025% still experiencing) Dysesthesia: 8.8% incidence (mild) Body adapting well For 12mg group (final increase): GI effects may temporarily worsen (4045% nausea) Dysesthesia peaks (20.9% incidence) This is the "make or break" dose highest efficacy, highest side effects Duration: 12 weeks adjustment period Week 17+: Long-Term Maintenance Side effects: Nausea: Decreases to 1525% (down from 4045%) Diarrhea: Improves to 1020% Dysesthesia: Stable at 8.820.9% (doesn't worsen) Most people feel "normal" except for reduced appetite Key point: Side effects are WORST during dose escalation (weeks 116)
manufacturer savings available References Jastreboff AM, et al
In the AMY 1 R and AMY 3 R Y37 rAmy interacts with residues in the respective RAMP and the CTR ECD, however the small side chain of P37 Cagri is completely buried by the surrounding CTR ECD residues, forming extensive hydrophobic contacts with W79 ECD and no direct interactions with either RAMP1 (AMY 1 R) or RAMP3 (AMY 3 R), again consistent with the restrictive interactions formed by Pro32 sCT with the CTR ECD
An injection is one of the most effective ways to get B12 and is typically used for those who might not benefit from tablets, liquids or capsule supplements for any reason
Because the genetic side of the world and the stem cell side of the world and the biologic side of the world and all of these things, and then you break in the large language model side and wearables and the ability to track in real time
